Edgar Filing: STRYKER CORP - Form 8-K

# STRYKER CORP

Form 8-K June 05, 2012

**UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# FORM 8-K

# **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 31, 2012

# STRYKER CORPORATION

(Exact name of registrant as specified in its charter)

0-9165 Michigan 38-1239739 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

49002 2825 Airview Boulevard, Kalamazoo, Michigan (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 269.385.2600

Check the appropriate box below if the Form 8-K	filing is intended	to simultaneously	satisfy the filing	g obligation of
the registrant under any of the following provision	ns:			

the r	egistrant under any of the following provisions:	
[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	

- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: STRYKER CORP - Form 8-K

### ITEM 8.01 OTHER EVENTS

As previously disclosed, in 2010 we received a subpoena from the United States Department of Justice (DOJ) related to the sales and marketing of the OtisKnee device. The subpoena concerns allegations of violations of Federal laws related to sales of a device not cleared by the United States Food and Drug Administration. We recently entered into discussion with the DOJ regarding the potential settlement of this matter, and on May 31, 2012 we offered \$33 million to the DOJ. During the second quarter of 2012 we will record a non-tax deductible charge of \$33 million representing our best estimate of the minimum of the range of probable loss to resolve this matter. There can be no assurance that we will reach a consensual resolution, when such a resolution would occur, or what the final terms of any such resolution may be.

The charge is expected to reduce our reported diluted net earnings per share by approximately \$0.09 for the second quarter of 2012 and will be excluded from our adjusted diluted net earnings per share.

### FORWARD LOOKING STATEMENTS

Certain statements above may contain information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause the Company's actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for the Company's products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for the Company's products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; resolution of tax audits; changes in financial markets; changes in the competitive environment; the Company's ability to integrate acquisitions; and the Company's ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors are contained in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STRYKER CORPORATION (Registrant)

June 5, 2012 Date /s/ Curt R. Hartman
Curt R. Hartman
Interim Chief Executive Officer and Vice
President and Chief Financial Officer